MMAF intermediate 2

• Description :

  MMAF intermediate 2 is an intermediate for the synthesis of MMAF (HY-15579) . MMAF (Monomethylauristatin F) is a potent inhibitor of tubulin polymerization and the cytotoxic (ADC Cytotoxin) component of classic antibody drug conjugates (ADCs), such as Vorsetuzumab mafodotin and SGN-CD19A[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  ADC Payload

• Type :

  Reference compound

• Related Pathways :

  Antibody-drug Conjugate/ADC Related

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/mmaf-intermediate-2.html

• Purity :

  99.77

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(N[C@H](C(OC)=O)CC1=CC=CC=C1)[C@H](C)[C@@H](OC)[C@H]2NCCC2.Cl

• Molecular Formula :

  C19H29ClN2O4

• Molecular Weight :

  384.90

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Lee JW, et al. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res. 2010 May 1;16 (9) :2562-70. [Content Brief]

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, stored under nitrogen)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [864238-20-0]